Precision genome editing strategies for enduring lipid lowering in atherosclerosis
Authors:
- Durlav ChowdhuryDCDurlav Chowdhury
- Nirdesh SinghNSNirdesh Singh
- Swarnalata GaraiSGSwarnalata Garai
- Devi Prasad PandeyDPDevi Prasad Pandey
- Surendra H. BodakheSBSurendra H. Bodakhe
- 3 September 2026
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1034
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Prime editing: Emerging mechanisms, engineering innovations, and next-generation applicationsBioDesign Research, 2026
- In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular diseaseMolecular Therapy Nucleic Acids, 2025
- Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies – challenges and opportunitiesJournal of Controlled Release, 2024
- Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9Trends in Cardiovascular Medicine, 2021
- AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene TransferMolecular Therapy, 2020
- Animal models of atherosclerosisEuropean Journal of Pharmacology, 2017
- A Test in Context: Lipoprotein(a)JACC, 2017
- Applications and Limitations of Mouse Models for Understanding Human AtherosclerosisCell Metabolism, 2017
- In vivo genome editing using Staphylococcus aureus Cas9Nature, 2015
- Genetics of atherosclerosisTrends in Genetics, 2012